A modeling study projected that HPV vaccination programs for adults aged 27 to 45 years could benefit subgroups at higher risk for HPV, but overall, the approach is more costly and less effective than vaccinating younger people. According to the authors, this is the first study to examine the cost-effectiveness and HPV-related cancer prevention of vaccinating subgroups of adults in this age group at higher risk of HPV infection in the US. The findings are published in Annals of Internal Medicine.
This article was originally published on MedicalXpress.com
